Pharma’s 340B Dispute Resolution Arguments May Get Boost From Supreme Court’s Patent Ruling
Executive Summary
As stakeholders begin to mull the impact of the Arthrex opinion, HHS withdraws its advisory opinion concluding manufacturers are legally bound to provide 340B discounts to contract pharmacies, and Lilly takes aim at 340b contract pharmacy ‘replenishment’ model.
You may also be interested in...
Stock Watch: Gaming The US Health Care System
The pharmaceutical sector is often unfairly demonized in the drug pricing debate. Other participants exploit the complex US health care system almost with impunity.
US Supreme Court Gives PTO Director Chance To Impact Outcome Of Patent Disputes
High court finds PTAB judges were unconstitutionally appointed; ruling is unlikely to benefit one party over another in inter partes review proceedings, attorneys say, but that could depend on the director. PTO is expected to provide guidance on how and when to request review of Patent Trial and Appeal Board decisions.
340B Contract Pharmacy Feud: Court Undercuts HHS Position Against Drug Firms In Ruling
Federal district court denies HHS request to dismiss AstraZeneca’s lawsuit, but also suggests Congress needs to clarify the contract pharmacy issue.